

# Resource Summary Report

Generated by [RRID](#) on Aug 21, 2026

## [pBOBI-FLuc](#)

RRID:Addgene\_170674

Type: Plasmid

### Proper Citation

RRID:Addgene\_170674

### Plasmid Information

**URL:** <http://www.addgene.org/170674>

**Proper Citation:** RRID:Addgene\_170674

**Insert Name:** luc

**Organism:** firefly

**Bacterial Resistance:** Ampicillin

**Defining Citation:** [PMID:32540903](#)

**Vector Backbone Description:** Backbone Marker:from Han lab; Backbone Size:8800; Vector Backbone:pBOBI\_cs2.0; Vector Types:Mammalian Expression, Lentiviral, Luciferase; Bacterial Resistance:Ampicillin

**Plasmid Name:** pBOBI-FLuc

**Record Creation Time:** 20220422T221953+0000

**Record Last Update:** 20260815T081010+0000

### Ratings and Alerts

No rating or validation information has been found for pBOBI-FLuc.

No alerts have been found for pBOBI-FLuc.

### Data and Source Information

**Source:** [Addgene](#)

### Usage and Citation Metrics

We found 12 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Wasdin PT, et al. (2025) Generation of antigen-specific paired-chain antibodies using large language models. *Cell*, 188(25), 7206.

Zhou P, et al. (2025) Directed evolution of a stem-helix-targeting antibody enables MERS-CoV cross-neutralization through enhanced binding affinity. *bioRxiv : the preprint server for biology*.

Wasdin PT, et al. (2025) Generation of antigen-specific paired chain antibody sequences using large language models. *bioRxiv : the preprint server for biology*.

Sheward DJ, et al. (2024) Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies. *Cell reports. Medicine*, 5(6), 101577.

Dacon C, et al. (2023) Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. *Cell host & microbe*, 31(1), 97.

Pushparaj P, et al. (2023) Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies. *Immunity*, 56(1), 193.

Zhou P, et al. (2023) Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. *Immunity*, 56(3), 669.

Sheward DJ, et al. (2023) Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses. *The Lancet. Infectious diseases*, 23(11), e462.

Wall SC, et al. (2023) SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes. *Cell reports. Medicine*, 4(11), 101267.

Hanke L, et al. (2022) Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies. *Science advances*, 8(12), eabm0220.

Gupta G, et al. (2022) Silver nanoparticles with excellent biocompatibility block pseudotyped SARS-CoV-2 in the presence of lung surfactant. *Frontiers in bioengineering and biotechnology*, 10, 1083232.

Sheward DJ, et al. (2022) Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. *The Lancet. Infectious diseases*, 22(6), 813.